Purpos e: To evaluate the efficacy and toxic ity of co mbinatio n c he mothe rapy w ith low-dose pac litaxe l and cis platin in patie nts w ith advanced no n-s mall cell lung cance r.
INTRODUCTION
Despite great efforts in terms of clinical investigation over the past decades, the treatment options for patients with metastatic (stage IV) or locally advanced (stage IIIB) non-small cell lung cancer (NSCLC) remain limited. Survival rates for patients with NSCLC stage IIIB or IV have remained unchanged and poor (1) . Although the current 5-year survival rates of 4% to 8% for patients with stage IIIB disease and less than 1% for those with stage IV disease are disappointing (2) , there have been some encouraging advancements in the treatment of NSCLC. Cisplatin-based chemotherapy in combination with other active drugs has resulted in both a higher response rate and better survival than combinations without cisplatin (3) . Overall, however, the therapeutic impact of cisplatin on NSCLC has been modest, emphasizing the need for continued efforts to improve systemic therapy for this disease.
Paclitaxel (Taxol ) is the first available compound of a new class of antitumor agents, the taxanes, which act by inducing the polymerization of tubulin both in vitro and in vivo (4, 5) . Several phase II studies of single-agent paclitaxel have been performed in chemotherapy-naive patients with NSCLC stage IIIB and IV (6 8) . These studies, in which paclitaxel has been administered at doses ranging from 200 to 250 mg/m 2 every 21 days, as either a 24-hour infusion or a 3-hour infusion, indicate that paclitaxel is active in NSCLC.
Since paclitaxel exerts its cytostatic effect via a mechanism different from that of cisplatin, and because paclitaxel does not share the nephrotoxicity or ototoxicity of cisplatin, it appears reasonable to combine the two drugs. A clinical phase I trial evaluating paclitaxel (24 hour infusion) combined with cisplatin has been performed and demonstrated that there was less toxicity when paclitaxel was administered before cisplatin (4) . In addition, a synergistic interaction between paclitaxel and cisplatin has been reported from in vitro studies (5) . von Pawel et al also performed a phase II clinical study of paclitaxel/ cisplatin and reported a major response rate of 42% and 1-year survival rate of 33% (9) .
Based on this data, major clinical oncology study groups compared the combination of paclitaxel and cisplatin with the old standard regimens: cisplatin and etoposide, cisplatin and teniposide, and high-dose cisplatin. They reported improved clinical response or superior survival for the combination of paclitaxel and cisplatin, which is now recognized as the standard regimen. However, the incidence of hematologic and non-hematologic toxicities was high (10 12) . Grade 3/4 neutropenia developed in about 40 55% of patients and grade 3/4 neuropathy in 9 23% of patients. In order to reduce the toxicity and maintain the efficacy, researchers have explored a variety of doses and varying schedules for the administration of paclitaxel. Hsu et al reported a response rate of 50.0% and minimal hematologic and non-hematologic toxicities using the combination of cisplatin and a low-dose (135 mg/m 2 ), 3-hour infusion of paclitaxel (13) . Our study also tested the possibility of a combination of cisplatin and low-dose paclitaxel to reduce the toxicity and maintain the efficacy.
MATERIALS AND METHODS
Patients with histologically or cytologically proven, measurable or evaluable NSCLC stage IIIB or IV were candidates for this study. Those who presented recurrent disease after surgical resection were also included. Patients were allowed to have had previous radiation, provided it had been completed 4 weeks before study entry, however patients whose only measurable lesion was within a radiated field were ineligible. Patients who had taken previous chemotherapy were excluded. Eligibility criteria further required an ECOG performance status of 0, 1, or 2 and adequate hematologic (granulocyte count 1,500/ L, platelet count 100,000/ L), hepatic (bilirubin 1.25 upper normal limit), and renal (serum creatinine 1.25 upper normal limit) functions. Patients had to be at least 18 years of age and should have a life expectancy of at least 12 weeks. Additionally, patients could not have any coexistent medical problem of sufficient severity to prevent full compliance with the study and should have no previous history of malignant disease, with the exception of skin cancer or carcinoma-in-situ of the cervix. All patients gave written informed consent before the start of chemotherapy. Patients were ineligible if they had any of the following: a history of atrial or ventricular arrhythmia, severe congestive heart failure, or myocardial infarction; preexisting motor and sensory neuropathy of World Health Organization (WHO) grade 2; active bacterial, viral, or fungal infection; or serious underlying medical conditions that would impair their ability to receive protocol treatment, including prior allergic reactions to Cremophor-containing drugs. Fertile patients who were not using contraceptives, and pregnant or lactating women were also ineligible.
All patients received premedication with hydrocortisone, pheniramine, and famotidine. Hydrocortisone 100 mg, pheniramine 45.5 mg, and famotidine 20 mg were administered as an intravenous bolus injection 30 minutes before infusion of paclitaxel. Patients received paclitaxel 145 mg/m 2 dissolved in 500 mL 5% glucose and administered by continuous infusion over 3 hours. After overnight hydration and standard prehydration, patients then received cisplatin 60 mg/m 2 over 15 minutes, followed by 2 hours of posthydration. A standard antiemetic regimen with 5HT3-antagonists was also administered. The treatment was repeated every 21 days provided there was recovery from toxicity and no evidence of disease progression. History and physical examination, complete blood count, and serum chemistries were performed before each treatment cycle. Disease response was evaluated with a chest X-ray before each cycle and with a chest computed tomographic (CT) scan every 2 3 cycles. Patients with complete or partial response received two further cycles; patients with stable disease received a maximum of six cycles. Treatment was discontinued if the disease progressed. Toxicity and tumor responses were defined according to WHO criteria (14) . Survival estimates were calculated by the Kaplan-Meier method.
RESULTS
Between February 2000 and February 2001, 42 patients were entered into the trial. The characteristics of the 42 enrolled patients are listed in Table 1 . There were 27 men and 15 women, with a median age of 53.5 years (age range, 32 to 65) and a median ECOG performance status of 1 (range, 0 to 2). 17 patients had stage IIIB, and 19 had stage IV disease. Six patients presented with recurred disease with distant metastasis after surgical resection (lobectomy: 4 and pneumonectomy: 2). The predominant histology was adenocarcinoma (69.0%). 23.8% of the patients had lost more than 5% of their usual body weight during the 6 months before entry into the study.
The lung was the most frequent distant metastatic site (10/42=23.8%) followed by bone (7/42=16.7%). Seven patients had received previous chest radiation (4: postoperative radiation, 2: obstructive pneumonia, 1: SVC syndrome). Four patients had pericardial effusion and three of these required pericardiocentesis.
1) Response and survival
The 42 patients received a total of 176 courses of paclitaxel/ cisplatin combination. The median number of cycles administered was 4.5 (range, one to twelve). Fourteen patients (33.3%) received the planned maximum of six courses due to favorable responses; three patients (7.1%) received seven courses, and one patient received twelve courses. Four patients were not evaluable for response, 1 because of hypersensitivity reaction and 3 due to severe emesis. Objective antitumor responses are listed in Table 2 . The objective response rate for the 38 assessable patients was 36.8%, with no complete responses and 14 partial responses. Six of 14 patients who had attained partial response received additional chest radiation. Their data was not included in the calculation of median response duration, which was 47.9 weeks (Fig. 1) . With a minimum follow-up duration of 5.3 months, the median overall survival time was 54.0 weeks and the 1-year survival rate was 50.4% (Fig. 2) .
2) Toxicity
Of a total of 176 courses, 14 courses were delayed primarily due to insufficient hematologic recovery and 22 courses required a 25% dose reduction. WHO grade 3 or 4 neutropenia occurred in 5.6% of courses (Table 3) . However, thrombocytopenia and anemia remained infrequent throughout the study, with no grade 3 or 4 toxicity. Neutropenic fever occurred in only one patient and there was no treatment-related mortality. Nonhematologic toxicity, including nausea/vomiting and neuropathy, was generally mild. WHO grade 3 or 4 nausea/ vomiting occurred in 11.9% of patients and only 3 patients suffered from grade 3 neuropathy (Table 4) . Grade 3 alopecia occurred in 19 patients. The cases of oral mucositis and diarrhea were confined to patients with grade 2 or lower toxicity. Three patients refused to receive further treatment because of grade 4 emesis, although no patients refused chemotherapy due to neuropathy. Hypersensitivity reaction occurred in two patients: one terminated treatment, while the other received a 24-hour infusion of paclitaxel and subsequently exhibited no further hypersensitivity reaction.
3) Salvage treatment
Many patients received salvage chemotherapy or radiation after they failed in the paclitaxel/cisplatin combination. Ten patients received salvage chest radiation and five patients received brain radiation. Various chemotherapy regimens were performed and the most frequently used agent was vinorelbine (18 patients) followed by gemcitabine (11 patients) then ifosfamide (9 patients) and docetaxel (5 patients). Two patients received intrathecal methotrexate due to leptomeningeal carcinomatosis.
DISCUSSION
NSCLC continues to be a major health problem in developed countries. Although the incidence in males generally seems to be leveling off, the incidence in females continues to increase (1) . At the time of diagnosis, the majority of patients will be diagnosed with metastatic (stage IV) or locally advanced (stage III) disease. Thoracic radiotherapy, generally considered as the standard therapy for inoperable, locally advanced disease, has a limited impact on survival, and most patients will develop distant metastatic disease. Consequently, most patients diagnosed with NSCLC are potential candidates for chemotherapy trial.
Among the agents considered active in the treatment of advanced NSCLC, cisplatin has been reported to produce a response rate of up to 20%. Moreover, cisplatin-based combination regimens have demonstrated some improvement in survival when compared with non-platinum-containing regimens (3). However, there is a definite need for more effective chemotherapy to treat NSCLC.
Paclitaxel has been shown to have a unique mechanism of antitumor action; it promotes microtubule assembly and stabilization. The safety profile, as well as the anticancer activity, of paclitaxel in patients with advanced malignancies has been well established. Paclitaxel has been evaluated in the treatment of patients with advanced NSCLC in several phase II trials. In these trials, it has yielded response rates greater than 20% and it has been associated with notable 1-year survival rates (6 8) . Preclinical studies that evaluated paclitaxel-based combination regimens have shown a synergistic antineoplastic effect for the paclitaxel/cisplatin combination (5). In addition, clinical phase I studies evaluating paclitaxel/cisplatin have shown the feasibility and modest efficacy of the combination (4, 15, 16) . EORTC performed a phase II clinical study of paclitaxel/cisplatin and reported a major response rate of 42% and 1-year survival rate of 33% (9) .
Large-scale phase III studies conducted by ECOG demonstrated improved survival as compared to the etoposide/ paclitaxel combination (11), whereas two other studies performed by EORTC showed an improved response rate and progression free survival but failed to suggest an improved overall survival as compared to teniposide/paclitaxel in combination or a high-dose cisplatin regimen (10, 12) . This is explained by the fact that more patients are eligible to receive the 2 n d line chemotherapy including taxanes. The response rate of 36.8% and the 1-year survival rate of 50.4% experienced in this study compare favorably with results obtained using other regimens in advanced NSCLC (17 19) . The other Korean study of paclitaxel/cisplatin in advanced NSCLC reported a response rate of 58%, a median response duration of 21 weeks and a median overall survival of 28 weeks, which is better than our study in terms of response rate, although the response duration and survival are shorter. Other clinical studies performed recently in Korea in the field of advanced NSCLC have primarily been concerned with the vinorelbine and platinum-compound combination and have reported outcomes similar to those of our study (20 22) . In addition, the toxicities of this regimen were modest and for the most part, easily managed. The most common hematologic toxicity was grade 3 or 4 neutropenia, which developed in 5.6% of the treatment courses. Neutropenic fever occurred in one patient and there were no treatment-related deaths. Neurotoxicity occurred, but was mostly WHO grade 1 or 2, even with the 3-hour paclitaxel infusion.
CONCLUSIONS
The results of our study suggest that the low-dose paclitaxel/ cisplatin combination was effective for treating advanced NSCLC with reduced toxicity. A new study comparing paclitaxel and other new chemotherapeutic agents such as vinorelbine or gemcitabine is required to optimize the treatment of NSCLC. 
